Detection of MAFLD in Patients with Isolated AntiHBC Ig G Positive Hepatitis B Who Need Immunosuppressive Therapy

INTRODUCTION: With the current consensus approach, the definition of non-alcoholic fatty liver disease has been changed to 'fatty liver disease associated with metabolic dysfunction' (MAFLD). This study aimed to investigate the company of MAFLD in isolated AntiHBC Ig G positive hepatitis B patients who need immunosuppressive therapy for various reasons. METHODS: The presence of MAFLD was prospectively investigated before starting treatment in 150 patients with isolated AntiHBC IgG positivity who needed immunosuppressive therapy for a reason such as a rheumatological disease or tumor. All patients were scanned with Fibroscan M530 before immunosuppressive therapy and CAP value was determined. Simultaneously, blood lipid level, HOMA score, fasting insulin and fasting blood glucose were measured. RESULTS: Oral antiviral therapy was started in all patients who needed immunosuppressive therapy and had isolated AntiHBc IgG positivity. CAP was measured with fibroscan M530 in all patients included in this study.This situation is accepted as F: 0-1 according to metavir. The patients' average CAP value was 235.2 dB/m with the exact measurement. In this case, although the mean value was <248 dB/m, MAFLD was detected in 28.1% of the cases. DISCUSSION AND CONCLUSION: In this study, MAFLD was found in 28.1% of patients with low liver fibrosis but isolated AntiHBc IgG positivity requiring immunosuppressive treatment and to be started oral antiviral to prevent HBV reactivation.